Hikma Pharmaceuticals (OTCMKTS:HKMPF) Hits New 1-Year Low - Should You Sell?

Key Points

• Hikma Pharmaceuticals shares have reached a new 52-week low of $22.36, down by 2.0% from the previous close of $22.91.
• The company operates through three segments: Injectables, Generics, and Branded, focusing on a range of pharmaceutical products.
• Current financial metrics include a current ratio of 1.24 and a debt-to-equity ratio of 0.33, indicating moderate liquidity and low leverage.

Shares of Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF - ) reached a new 52-week low on Friday . The company traded as low as $22.36 and last traded at $22.36, with a volume of 765 shares changing hands. The stock had previously closed at $22.91.

Hikma Pharmaceuticals Stock Down 2.0%

The company has a current ratio of 1.24, a quick ratio of 0.72 and a debt-to-equity ratio of 0.33. The stock has a fifty day simple moving average of $25.81 and a two-hundred day simple moving average of $26.56.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.